News

In vitro, ITI-007 was shown to be a potent, sub-nanomolar, antagonist at 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ITI-007

The patent purports to claim methods for creating an index of a subject’s biological state pertaining to inflammation. XDx’s request states that a combination of prior art references

The companies are collaborating to perfect the required marketing applications to the local regulatory authorities. It is anticipated that the marketing of Catrix wound dressing will commence in

Simcor is approved for use along with diet to lower levels of elevated total cholesterol, low-density lipoprotein (LDL) ‘bad’ cholesterol and triglycerides, and to raise high-density lipoprotein (HDL)

The company claims that CMS, with several leading solutions in clinical use and a strong pipeline of advanced functionality in development, will significantly contribute to Elekta’s strategy in

The randomized, double-blind, active (hydrocortisone) controlled, 17 patient study demonstrated that TF002 met its primary endpoint of significant reduction of inflammation in atopic skin. The anti-inflammatory effect was

The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced

In this new agreement, both NRDL and Lilly will independently carry out early clinical development of two different candidate compounds directed against the same target. Following the evaluation

A new variant of liposomal doxorubicin, Nudoxa with its unique drug delivery system is said to be a breakthrough in cancer therapy as it offers the benefits of